Following the successful launch of Nabota (Clostridium Botulinum Toxin Type A), Daewoong Pharma Phils., the exclusive marketing arm of Nabota in the Philippines reinforces its partner doctors with the official release of its NABOTA EXPERT’S JOURNAL.
The “Expert’s Journal” is aimed at enhancing the skills of doctors on proper documentation when injecting toxin and filler. It also seeks to educate doctors on facial anatomy and proper position of filler and toxin. Morever, the Expert Journal will include precautionary measures during complications and how to avoid it.
The launch of Nabota Expert’s Journal will take place before selected media delegates, Nabota clinical advisors, partner doctors, and officials from Daewoong Pharma.
The Expert Journal is complementary to Nabota’s world-class standards. Developed from bio-technology of over 30 years of know-how and manufactured from Daewoong’s world class GMP, Nabota is the latest Clostridium Botulinum Toxin Type that boasts of High Purity at 98.7 % which is the highest in the field today.
Daewoong revolutionized the production of botulinum toxin through a patented process. Nabota was produced in a Good Manufacturing Practice (GMP) facility to ensure that it delivers the highest quality of botulinum toxin possible. Nabota secured the international standard quality with the latest patent. Nabota boasts of 100% botulinum toxin complex, with no impurities.
Two months after the launch of Nabota last June 25, it has already dominated most areas in the Philippines and has exceeded their target for the quarter. Given the success in the local market, it’s country brand manager, Christopher Cachuela plans to be more aggressive towards expanding its sales field force to reach all major cities by the end of this year.
To learn more about NABOTA, visit www.nabota.info